Information Links
Guidelines - Central nervous system
Quick-reference summaries of key national treatment guidance for neurological and psychiatric conditions including multiple sclerosis and bipolar disorder.
MIMS summaries
At-a-glance summaries of authoritative evidence-based clinical guidelines for neurological and psychiatric conditions commonly encountered in primary care, prepared by the MIMS editorial team.
Assessing Fitness to Fly (CAA Guidance)
Key advice from the Civil Aviation Authority (CAA)...
Current Medical Standards of Fitness to Drive (DVLA Guidance)
Key advice from DVLA on fitness to drive.
NICE technology appraisals
Decisions by the National Institute for Health and Care Excellence on NHS access to treatments for neurological and psychiatric conditions.
-
Daclizumab for Treating Relapsing-Remitting Multiple Sclerosis (TA441)
-
Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (TA217)
-
Vortioxetine for Treating Major Depressive Episodes (TA367)
-
Dimethyl Fumarate for Treating Relapsing-Remitting Multiple Sclerosis (TA320)
-
Alemtuzumab for Treating Relapsing-Remitting Multiple Sclerosis (TA312)
-
Teriflunomide for Treating Relapsing-Remitting Multiple Sclerosis (TA303)
-
Aripiprazole for Treating Moderate to Severe Manic Episodes in Adolescents with Bipolar I Disorder (TA292)
-
Botulinum Toxin Type A for the Prevention of Headaches in Adults with Chronic Migraine (TA260)
-
Fingolimod for the Treatment of Highly Active Relapsing-Remitting Multiple Sclerosis (TA254)
-
Aripiprazole for the Treatment of Schizophrenia in People Aged 15 to 17 Years (TA213)
-
Multiple Sclerosis, Relapsing-Remitting: Natalizumab (NICE)
-
ADHD: Methylphenidate, Atomoxetine, Dexamfetamine (NICE)
-
Motor Neurone Disease: Riluzole (Rilutek) (NICE)
-
Insomnia: Zaleplon, Zolpidem and Zopiclone (NICE)
-
Multiple Sclerosis: Beta Interferon and Glatiramer Acetate (NICE)
MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.